4th Quarter - Termination

RAMPY NORTHRUP LLC for ASTRAZENECA PHARMACEUTICALS LP

Firm
Client
Income
$60,000
Expenses
—
Terminated
Dec 31, 2022

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Provide legislative and regulatory advice related to vaccine development, drug pricing, the 340B Drug Pricing Program, PDUFA Reauthorization, and clinical trial diversity; H.R.6000, Cures 2.0 Act; H.R.5585, Advanced Research Project Agency-Health Act; H.R.5030/S.2706, DIVERSE Trials Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.7559, Prescription Information Modernization Act of 2022; H.R.2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021; H.R.2617, Consolidated Appropriations Act, 2023.

LobbyistCovered position, as disclosed
STACEY RAMPY —

Contacted: HOUSE OF REPRESENTATIVES

Bills named: H.R. 2873 (117th), H.R. 5030 (117th), H.R. 7559 (117th), H.R. 2617 (117th), S. 2706 (117th), S. 4348 (117th), H.R. 7667 (117th), H.R. 5585 (117th), H.R. 6000 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.